Experimental cancer drug begins human testing for Tough-to-Treat tumors
NCT ID NCT07419841
Summary
This is the first human study of an experimental drug called CTX-10726 for patients with advanced cancers that have stopped responding to standard treatments. The trial will test increasing doses of the drug to find the safest amount and see how the body processes it. Researchers will also look for early signs that the drug might help shrink tumors in patients with specific advanced cancers including kidney, liver, stomach, and endometrial cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nebraska Cancer Specialists
NOT_YET_RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START New York
RECRUITINGLake Success, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.